1C
KALA icon

1623 Capital’s KALA BIO KALA Stock Holding History

1623 Capital’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8
Closed -$135K – 80
2021
Q1 		$135K Buy
+8
New +$156K 0.06% 63

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

1623 Capital's KALA Position: Q2 2021 in Review

1623 Capital sold out of KALA BIO (KALA) in Q2 2021, closing a stake of 8 shares — an estimated $135K sold.

1623 Capital first reported a position in KALA in Q1 2021 and held it in 1 quarter. The position peaked at $135K in Q1 2021. 97 funds tracked by Wall St. Rank hold KALA as of Q2 2021.

  • 1623 Capital reported no remaining KALA BIO position as of Q2 2021 after selling out during the quarter.
  • 1623 Capital sold 8 KALA BIO shares in Q2 2021, an estimated $135K.
  • 1623 Capital first reported a position in KALA BIO in Q1 2021 and held it in 1 quarter.
  • 1623 Capital's KALA BIO position peaked at $135K in Q1 2021.
  • 97 funds tracked by Wall St. Rank held KALA BIO as of Q2 2021.

Based on 1623 Capital's 13F filing for Q2 2021, filed 13 Aug 2021.